Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (8049)	7/6/2001 8:15:32 PM
From: BinkY2K	Respond to of 10293

Congratulations Hank, and Peter too! I went look on the front page to see Hank as Cool Post of the day and I see Peter got cool Post for Today for Replying to Hank! LOL! I think I know why the people who choose were reading this thread. They found serious discussions and apparently liked it.

To: Hank who wrote (8049)	7/6/2001 8:31:53 PM
From: BinkY2K	Read Replies (1) \| Respond to of 10293

Hank, about traders. I do not claim deep expertise here. You seem to be talking more about day traders. Many I knew have gone back to working at their real jobs or even went out and GOT a job. Yet, as many regular folks have left the market, the percentage of all trades made by day traders on the NAZ seems to have doubled. There may be a second group of BIG traders that include the hedge funds and many mutual funds too, as well as trading departments in major brokerages. These are the ones I suspect of often acting in concert and often using shills like CNBC to help spread the mood they want. I think these guys are not so much into day trading as cycle trading and they want volatility over a period of perhaps weeks. Your points about the drug and biotech sectors seem to boil down to size. You seem to like big companies. They may be more stable. I used to own Merck for years for those reasons and did well and sold it in time. Peter indicates that my thoughts about multiple drugs solving similar problems is not likely to happen and the first company tends to still sell plenty. Maybe. But over the lifetime of the patent, the others can eat into profits, especially if they have fewer side effects. I am starting to wonder if the way to more safely play Biotech is to buy an assortment of the bigger names, or a sector fund.